Clinical Prophylaxis

Dr. Thierry Lambert
MD

Dr Thierry Lambert is a consultant in hematology, specialized in hemophilia and rare constitutional bleeding disorders. After having been medical director of blood transfusion service in the Bicêtre AP-HP Hospital, Paris, France until 1997, he then acted as Director of the Regional Hemophilia Treatment Center (CRTH) in the same location and was Regional Hemophilia Coordinator. He is a member of the Steering Committee of the European Hemophilia Safety surveillance (EUHASS). He is also co-chair of the international working group on prophylaxis (IPSG) and member of the scientific committee of the French Hemophilia Association (AFH), national patient organization, member of the WFH. Principal investigator or sub investigator in more than ten studies focusing on the treatment of hemophilia.

Key Publications

Practical aspects of extended half-life products for the treatment of haemophilia.

Lambert, T ; Benson, G ; Dolan, G ; Hermans, C ; Jiménez-Yuste, V ; Ljung, R & al

Ther Adv Hematol 2018

 

Prophylaxis re-visited: the potential impact of novel factor and non-factor therapies on prophylaxis.

Carcao, M ; Lambert, T ; Leissinger, C ; Escuriola-Ettingshausen, C ; Santagostino, E ; Aledort, L

Haemophilia 2018

 

A national French non interventional study to assess the long-term safety and efficacy of reformulated nonacog alfa.

Lambert, T ; Rothschild, C ; Volot, F ; Borel-Derlon, A ; Trossaërt, M ; Claeyssens-Donadel, S & al

Transfusion 2017

 

Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors

Jimenez-Yuste Victor Auerswald Gunter ; Benson Gary ; Dolan Gerry ;Lambert Thierry Santagostino ElenaZupancic Salek Silva

Haemophilia 2021

Current Positions/Chairs:

  • Consultant
    Partial-time

Key Institutions

  • Hôpital Bicêtre, APHP
    Université Paris Saclay
    Le Kremlin-Bicêtre, France
  • Centre de Référence de l’Hémophilie
  • Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles rares .CRH, CRC-MHC

Research Activities

  • Principal investigator or sub investigator in more than ten studies and clinical trials focused on the treatment of hemophilia.

Research Interests

  • Focus on paediatric hemophilia, joint expression of hemorrhagic diseases and their treatment, and anti-FVIII inhibitors.